MTOR and breast carcinoma: Activation of mTOR signaling is a well-documented phenomenon associated with endocrine resistance and poor prognosis of ER+ breast cancer patients (Ciruelos Gil, 2014; Paplomata and O'Regan, 2014; Dong et al., 2021; Nunnery and Mayer, 2020).